Impact of body composition parameters on radiation therapy compliance in locally advanced rectal cancer: A retrospective observational analysis
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; none of the 32 sources its claims cite is checked for support yet.
Abstract
Background: The impact of body composition and sarcopenia in locally advanced rectal cancer (LARC) is still unclear, even several studies have been published on this issue. Our study aims to analyze the impact of sarcopenia on neoadjuvant chemoradiotherapy (nCRT) tolerance and survival outcomes. Methods: This is a retrospective, monocentric study where LARC patients treated between 2010 and 2020 were enrolled. A single slice, from the pre-therapy simulation computed tomography (CT) scan, was used to perform the body composition analysis with dedicated software. The primary endpoint was the impact of body composition on radiotherapy (RT) interruption secondarily on overall survival (OS), disease-free survival (DFS), and local control (LC). Results: The study included 628 LARC patients (40.9 % female, mean age 63.4 years): 24 % had low skeletal muscle index (SMI), 30 % had low muscle density (MD) and 17 (10.3 % of obese) were sarcopenic obese. Higher BMI (OR 2.38, 95 % CI 1.36-4.01) and lower SMI (0.73, 95 % CI 0.55-0.94) resulted as independent predictors of RT interruption. Sarcopenic obesity (HR 2.83, 95 % CI 1.24-6.45) was related to worse OS, while MD (0.96, 95 % CI 0.93-0.98), and higher SMI (0.97, 95 % CI 0.95-0.99) were related to better OS; a lower MD remained also associated even in adjusted multivariable analysis (0.96, 95 % CI0.93-0.98). Moreover, higher visceral adipose tissue (VAT) resulted associated with worse DFS (1.02, 95 % CI 1.01-1.03), while higher SMI was related to better Local Control (0.96, 95 % CI 0.93-0.99). Conclusions: Body composition analysis, particularly of muscle and fat masses, may be a useful tool for better management of LARC patients undergoing RT. Increased collaboration between radiation oncologists and clinical nutritionists is advisable, to enable early nutritional support of LARC.
Overview
CoChat Summary
TL;DR
In 628 patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy, higher BMI and lower SMI were independent predictors of radiotherapy interruption, while body composition parameters were also associated with survival outcomes. Higher muscle radiodensity was linked to better overall survival, higher visceral adipose tissue to worse disease-free survival, and higher SMI to better local control.
Key findings
- RT treatment was interrupted in 152 (23%) patients, with a mean interruption of 8.8 ± 6.9 days; 97 (15.4%) had an interruption of more than 5 days. Multivariable analysis identified BMI (OR 2.38, 95% CI 1.36–4.01; p=0.001) and SMI (OR 0.73, 95% CI 0.55–0.94; p=0.019) as independent factors for RT interruption.
- At a median follow-up of 68 months (95% CI 42.4–97.4), OS was 81.2% (95% CI 77.4–84.4), DFS was 71.7% (95% CI 67.4–75.5), and LC was 89.9% (95% CI 86.8–92.3). Higher MD was associated with better OS in multivariable Cox analysis (HR 0.96, 95% CI 0.93–0.98; p=0.023); sarcopenic obesity was associated with worse OS at univariate analysis (HR 2.83, 95% CI 1.24–6.45; p=0.01).
- Higher VAT was associated with worse DFS as an independent factor (OR 1.02, 95% CI 1.01–1.03; p=0.021); low VAT predicted worse DFS only in men (HR 1.65, 95% CI 1.06–2.61; p=0.029). Higher SMI was associated with better LC (HR 0.96, 95% CI 0.93–0.99; p=0.04).
- Baseline body composition: mean BMI was 26.3 ± 4.1 kg/m2; 165 (26.3%) were obese; 17 (2.7% of total; 10.3% of obese patients) had sarcopenic obesity; low SMI was present in 151 (24.0%) and low VAT in 251 (40.0%). Any GI toxicity occurred in 540 (85.9%), with G3 in 110 (17.5%) and G4 in 16 (2.6%).
Methods
- Single-center retrospective observational analysis of LARC patients (cT2-4 and/or cN0-1, cM0) treated between January 2010 and December 2019 at Fondazione Policlinico Gemelli IRCCS, Rome; 628 patients met inclusion criteria, including histopathologically confirmed rectal adenocarcinoma, age >18 years, available simulation CT, nCRT, surgery at least 8 weeks after nCRT, available staging, and follow-up of at least 2 years. nCRT was fluoropyrimidine-based with or without weekly oxaliplatin; RT dose to mesorectum and drainage nodes was 45 Gy/1.8 Gy per day, with tumor/mesorectum boost to 50.4 Gy or 55 Gy depending on technique.
- Body composition was assessed from the simulation CT at the third lumbar vertebra using SliceOmatic v5.0; SMA, IMAT, VAT, SAT, and MD were measured using predefined HU thresholds, and SMI, VAI, SAI, and IMAI were normalized to squared height. Low muscle mass was defined as SMI <52.4 cm2/m2 in men and <38.5 cm2/m2 in women; low VAT as <160 cm2 in men and <80 cm2 in women; the MD cutoff for OS was 28.6 HU by ROC/Youden analysis.
- Statistical analysis used STATA 14; normality was tested with Kolmogorov–Smirnov; continuous variables were compared with Student’s t-test or Mann–Whitney test, and proportions with Chi-Square or Fisher exact test. Variables with p<0.05 at univariate analysis entered multivariable logistic regression for RT interruption; Kaplan–Meier and multivariable Cox regression were used for survival outcomes; significance was p<0.05 (two-sided).
Limitations
- Stated by the authors: the study is retrospective and monocentric; it lacks information on pretreatment weight loss, inflammatory markers, and comorbidities; and it lacks correlation between nutritional status and postoperative complications or TME quality.
- Evident from the text: body composition was measured only from the radiotherapy simulation CT, so the analysis does not capture changes in muscle or fat during treatment; no external validation is reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 24 Not checked · 50 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interestingly, OS was lower in sarcopenic obese and underweight patients, rather than sarcopenic normal and overweight (Figure S7).”
§ Impact of body composition parameters on radiation therapy compliance in locally advanced rectal cancer: A retrospective observational analysis > Results > Survival outcomes
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“30.0 % of patients had MD under this cut-off.”
§ Impact of body composition parameters on radiation therapy compliance in locally advanced rectal cancer: A retrospective observational analysis > Results > Body composition analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MRF involvement (HR 1.91 95 % CI 1.24–2.95; p < 0.003)”
§ Impact of body composition parameters on radiation therapy compliance in locally advanced rectal cancer: A retrospective observational analysis > Results > Survival outcomes
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“DFS was 71.7 % (95 % CI 67.4 %-75.5 %) (Figure S3)”
§ Impact of body composition parameters on radiation therapy compliance in locally advanced rectal cancer: A retrospective observational analysis > Results > Survival outcomes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interestingly, a low VAT was identified as a predictor of worse DFS only in men (HR 1.65, 95 %CI 1.06–2.61; p: 0.029) (Table S1) (Figure S8).”
- Also stated in: § Discussion · plain
“Interestingly, a low VAT was identified as a predictor of worse DFS when a subgroup analysis was performed in men, according to the only other paper in the literature that explored this issue, in which the Authors hypothesized a possible explanation in the testosterone role [28].”
§ Impact of body composition parameters on radiation therapy compliance in locally advanced rectal cancer: A retrospective observational analysis > Results > Survival outcomes
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
43 more claims
Create a free account to see all 74 claims and to verify the 32 references still open.
- It may state two separate claims as one. 11
- Probably not a substantial claim. 21
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Impact of body composition parameters on radiation therapy compliance in locally advanced rectal cancer: A retrospective observational analysis > Results > Treatment adverse events
“RT treatment needed to be interrupted in 152 (23 %) patients”
§ Impact of body composition parameters on radiation therapy compliance in locally advanced rectal cancer: A retrospective observational analysis > Results > Treatment adverse events
“Univariate Analysis RT Interruption (137 patients)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“RT interruption | 152 (23)”
§ Impact of body composition parameters on radiation therapy compliance in locally advanced rectal cancer: A retrospective observational analysis > Results > Baseline Characteristic
Reported 23 · recomputed 24.203822
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Low VAT° | 80 (58.4) | 57 (41.6)”
§ Impact of body composition parameters on radiation therapy compliance in locally advanced rectal cancer: A retrospective observational analysis > Results > Treatment adverse events
Reported 58.4 · recomputed 16.494845
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“in 110 (15,9%) severe (G3)”
§ Impact of body composition parameters on radiation therapy compliance in locally advanced rectal cancer: A retrospective observational analysis > Results > Treatment adverse events
Reported 15.9 · recomputed 17.515924
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Low MD# | 245 (30.0)”
§ Impact of body composition parameters on radiation therapy compliance in locally advanced rectal cancer: A retrospective observational analysis > Results > Body composition analysis
Reported 30 · recomputed 39.012739
2 more findings
Create a free account to see every finding of this check.
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Egner, J. R. (2010) · JAMA · doi:10.1001/jama.2010.1525 · Cited by 5,997
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
Cederholm, T., Jensen, G. L., Correia, M. I. T. D., Gonzalez, M. C., Fukushima, R., Higashiguchi, T., Baptista, G., Barazzoni, R., Blaauw, R., Coats, A., et al. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.08.002 · Cited by 3,022 · cited 1×
“In 2016, leading clinical nutrition societies developed the GLIM (Global Leadership Initiative on Malnutrition) Criteria to establish a unified definition for the diagnosis of malnutrition [9].”
BackgroundCoiffier, B., Osmanov, E. A., Hong, X., Scheliga, A. A. D. S., Mayer, J., Offner, F. C., Rule, S. A., Teixeira, A., Walewski, J. A., de Vos, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70150-4 · Cited by 2,741
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583 · cited 1×
“Prior research has demonstrated that visceral obesity is linked to reduced testosterone levels in men, whereas women with high testosterone levels exhibit a positive association with visceral fat accumulation [41].”
BackgroundESPEN guidelines on definitions and terminology of clinical nutrition
Cederholm, T., Barazzoni, R., Austin, P., Ballmer, P., Biolo, G., Bischoff, S. C., Compher, C., Correia, I., Higashiguchi, T., Holst, M., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.09.004 · Cited by 2,560
Jensen, G. L., Cederholm, T., Correia, M. I. T. D., Gonzalez, M. C., Fukushima, R., Higashiguchi, T., de Baptista, G. A., Barazzoni, R., Blaauw, R., Coats, A. J. S., et al. (2019) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.1440 · Cited by 1,442
ESPEN expert group recommendations for action against cancer-related malnutrition
Arends, J., Baracos, V., Bertz, H., Bozzetti, F., Calder, P. C., Deutz, N. E. P., Erickson, N., Laviano, A., Lisanti, M. P., Lobo, D. N., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2017.06.017 · Cited by 1,305
Epidemiology of sarcopenia: Prevalence, risk factors, and consequences
Yuan, S., & Larsson, S. C. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155533 · Cited by 1,114 · cited 1×
“Sarcopenia, characterized by reduced muscle mass compared to individuals of the same age, gender, and race, is associated with adverse outcomes such as falls, fractures, physical disability, and mortality [11].”
BackgroundRödel, C., Graeven, U., Fietkau, R., Hohenberger, W., Hothorn, T., Arnold, D., Hofheinz, R.-D., Ghadimi, M., Wolff, H. A., Lang-Welzenbach, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00159-x · Cited by 726
Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2021.11.014 · Cited by 566 · cited 2×
“More recently, sarcopenic obesity (SO) has been defined as the coexistence of obesity (BMI greater than 30 kg/m 2 ) and sarcopenia by the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) [13].”
BackgroundBossi, P., Delrio, P., Mascheroni, A., & Zanetti, M. (2021) · Nutrients · doi:10.3390/nu13061980 · Cited by 465
Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study
Muscaritoli, M., the PreMiO Study Group, Lucia, S., Farcomeni, A., Lorusso, V., Saracino, V., Barone, C., Plastino, F., Gori, S., Magarotto, R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20168 · Cited by 438
Vecchio, F. M., Valentini, V., Minsky, B. D., Padula, G. D. A., Venkatraman, E. S., Balducci, M., Miccichè, F., Ricci, R., Morganti, A. G., Gambacorta, M. A., et al. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.11.017 · Cited by 423
Self-citationPetrelli, F., Trevisan, F., Cabiddu, M., Sgroi, G., Bruschieri, L., Rausa, E., Ghidini, M., & Turati, L. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000003471 · Cited by 395
de van der Schueren, M. A. E., Laviano, A., Blanchard, H., Jourdan, M., Arends, J., & Baracos, V. E. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy114 · Cited by 300
International consensus guidelines on Clinical Target Volume delineation in rectal cancer
Valentini, V., Gambacorta, M. A., Barbaro, B., Chiloiro, G., Coco, C., Das, P., Fanfani, F., Joye, I., Kachnic, L. A., Maingon, P., et al. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.07.017 · Cited by 256
Self-citationDoyle, S. L., Bennett, A. M., Donohoe, C. L., Mongan, A. M., Howard, J. M., Lithander, F. E., Pidgeon, G. P., Reynolds, J. V., & Lysaght, J. (2013) · Nutrition Research · doi:10.1016/j.nutres.2012.12.007 · Cited by 185
Sarcopenia is negatively associated with long‐term outcomes in locally advanced rectal cancer
Choi, M. H., Oh, S. N., Lee, I. K., Oh, S. T., & Won, D. D. (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12234 · Cited by 170
Rinninella, E., Cintoni, M., Raoul, P. C., Pozzo, C., Strippoli, A., Bria, E., Tortora, G., Gasbarrini, A., & Mele, M. C. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2019.10.021 · Cited by 161
Self-citationSun, G., Li, Y., Peng, Y., Lu, D., Zhang, F., Cui, X., Zhang, Q., & Zhuang, L. (2018) · International Journal of Colorectal Disease · doi:10.1007/s00384-018-3128-1 · Cited by 145
Gandham, A., Mesinovic, J., Jansons, P., Zengin, A., Bonham, M. P., Ebeling, P. R., & Scott, D. (2021) · Obesity Reviews · doi:10.1111/obr.13187 · Cited by 128
Impact of Visceral Obesity and Sarcopenia on Short-Term Outcomes After Colorectal Cancer Surgery
Chen, W., Chen, X.-D., Ma, L., Zhang, F., Lin, J., Zhuang, C., Yu, Z., Chen, X.-L., & Chen, X. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5019-2 · Cited by 99
Takeda, Y., Akiyoshi, T., Matsueda, K., Fukuoka, H., Ogura, A., Miki, H., Hiyoshi, Y., Nagasaki, T., Konishi, T., Fujimoto, Y., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195406 · Cited by 81
Insights into Pathogenesis, Nutritional and Drug Approach in Sarcopenia: A Systematic Review
Mellem, R. H., Girotto, O. S., Marques, E. B., Laurindo, L. F., Grippa, P. C., Mendes, C. G., Garcia, L. N. H., Bechara, M. D., Barbalho, S. M., Sinatora, R. V., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11010136 · Cited by 76
Ørsted, D. D., Nordestgaard, B. G., & Bojesen, S. E. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt590 · Cited by 75
Jochum, S. B., Kistner, M., Wood, E. H., Hoscheit, M. J., Nowak, L. L., Poirier, J., Eberhardt, J. M., Saclarides, T. J., & Hayden, D. M. (2019) · Colorectal Disease · doi:10.1111/codi.14751 · Cited by 72
(2020) · doi:10.4143/crt.2019.249 · Cited by 68
Chung, E., Lee, H. S., Cho, E., Park, E. J., Baik, S. H., Lee, K. Y., & Kang, J. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2019.03.014 · Cited by 58
Brown, D., Loeliger, J., Stewart, J., Graham, K. L., Goradia, S., Gerges, C., Lyons, S., Connor, M., Stewart, S., Di Giovanni, A., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.01.012 · Cited by 57 · cited 1×
“[4 ].”
Gao, Q., Hu, K., Gao, J., Shang, Y., Mei, F., Zhao, L., Chen, F., & Ma, B. (2022) · Nutrition · doi:10.1016/j.nut.2022.111704 · Cited by 56
Berkel, A. E. M., Klaase, J. M., de Graaff, F., Brusse-Keizer, M. G. J., Bongers, B. C., & van Meeteren, N. L. U. (2018) · Digestive Surgery · doi:10.1159/000490069 · Cited by 51
Prognostic value of sarcopenia in patients with rectal cancer: A meta-analysis
Zhu, Y., Guo, X., Zhang, Q., & Yang, Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270332 · Cited by 49
Rinninella, E., Fagotti, A., Cintoni, M., Raoul, P. C., Scaletta, G., Scambia, G., Gasbarrini, A., & Mele, M. C. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001215 · Cited by 40
Self-citationNardi, P. D., Giani, A., Maggi, G., & Braga, M. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i2.423 · Cited by 26
Diefenhardt, M., Ludmir, E. B., Hofheinz, R., Ghadimi, M. B., Minsky, B. D., Fleischmann, M., Fokas, E., & Rödel, C. M. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.09.028 · Cited by 23
(2021) · doi:10.1016/j.ejso.2021.10.008 · Cited by 22
Self-citationChiloiro, G., Romano, A., Mariani, S., Macchia, G., Giannarelli, D., Caravatta, L., Franco, P., Boldrini, L., ARCELLI, A., Bacigalupo, A., et al. (2023) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2023.100579 · Cited by 21
Self-citationLiu, Z., Lu, S., Wang, Y., Lin, X., Ran, P., Zhou, X., Fu, W., & Wang, H. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.796601 · Cited by 19
Kotti, A., Holmqvist, A., Woisetschläger, M., & Sun, X.-F. (2022) · Cancer & Metabolism · doi:10.1186/s40170-022-00297-6 · Cited by 14
(2021) · doi:10.5114/wiitm.2020.100880 · Cited by 5
Cited by
Zhang, Y., Zhang, J., Zhan, Y., Pan, Z., Liu, Q., & Yuan, W. (2024) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13629 · Cited by 37
Abdulla, A., Sadida, H. Q., Jerobin, J., Elfaki, I., Mir, R., Mirza, S., Singh, M. K., Macha, M. A., Shahab Uddin, M. S., Fakhro, K. A., et al. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.11.001 · Cited by 40
Chen, Y., Jia, H., Ye, R., Zhou, Z., Chen, W., Zheng, M., & Yuanyuan, Z. (2025) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13785 · Cited by 25
Mai, D. V. C., Drami, I., Pring, E. T., Gould, L. E., Rai, J., Wallace, A., Hodges, N., Burns, E. M., Jenkins, J. T., & On Behalf Of The BiCyCLE Research Group (2025) · Cancers · doi:10.3390/cancers17050846 · Cited by 11
Vonica, R. C., Butucă, A., Vonica-Țincu, A. L., Morgovan, C., Pumnea, M., Cipăian, R. C., Curca, R. O., Batâr, F., Vornicu, V., Solomon, A., et al. (2024) · Cancers · doi:10.3390/cancers16223847 · Cited by 11
Metadata
- Authors
- Chiloiro, G., Cintoni, M., Palombaro, M., Romano, A., Reina, S., Pulcini, G., Corvari, B., Di Franco, S., Meldolesi, E., Egidi, G., Grassi, F., Raoul, P., Rinninella, E., Gasbarrini, A., Mele, M. C., & Gambacorta, M. A.
- Affiliations
- Agostino Gemelli University Polyclinic (IT)
- Università Cattolica del Sacro Cuore (IT)
- Corresponding author
- Reina, Sara
- ORCID
- Venue
- Clinical and Translational Radiation Oncology
- Publisher
- Elsevier BV
- Published
- 2024-07
- Volume
- 47
- Pages
- 100789
- ISSN
- 2405-6308 (ISSN-L)
- PMC
- PMC11089307
- OpenAlex
- W4395957011
- Cited by
- 21
- References
- 44
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 5
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Clinical and Translational Radiation Oncology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Università degli Studi di Pavia
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Surgery › Colorectal and Anal Carcinomas
- Keywords
- locally advanced rectal cancer, body composition, sarcopenia, sarcopenic obesity, neoadjuvant chemoradiotherapy, skeletal muscle index, muscle density, visceral adipose tissue, overall survival, disease-free survival, local control, nutritional support, body mass index, obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
